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Abstract
The RV144 vaccine trial in Thailand demonstrated that an HIV vaccine could prevent infection in
humans and highlights the importance of understanding protective immunity against HIV. We
used a nonhuman primate model to define immune and genetic mechanisms of protection against
mucosal infection by the simian immunodeficiency virus (SIV). A plasmid DNA prime/
recombinant adenovirus serotype 5 (rAd5) boost vaccine regimen was evaluated for its ability to
protect monkeys from infection by SIVmac251 or SIVsmE660 isolates after repeat intrarectal
challenges. Although this prime-boost vaccine regimen failed to protect against SIVmac251
infection, 50% of vaccinated monkeys were protected from infection with SIVsmE660. Among
SIVsmE660-infected animals, there was an about one-log reduction in peak plasma virus RNA in
monkeys expressing the major histocompatibility complex class I allele Mamu-A*01, implicating
cytotoxic T lymphocytes in the control of SIV replication once infection is established. Among
Mamu-A*01–negative monkeys challenged with SIVsmE660, no CD8+ T cell response or innate
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immune response was associated with protection against virus acquisition. However, low levels of
neutralizing antibodies and an envelope-specific CD4+ T cell response were associated with
vaccine protection in these monkeys. Moreover, monkeys that expressed two TRIM5 alleles that
restrict SIV replication were more likely to be protected from infection than monkeys that
expressed at least one permissive TRIM5 allele. This study begins to elucidate the mechanism of
vaccine protection against immunodeficiency viruses and highlights the need to analyze these
immune and genetic correlates of protection in future trials of HIV vaccine strategies.
INTRODUCTION
The goal for an effective AIDS vaccine is to generate immunity that prevents the acquisition
of HIV-1. However, achieving this goal has proven elusive. Two clinical trials of an HIV-1
envelope (Env) protein immunogen showed no efficacy of this vaccine, and the
administration of a replication-defective adenovirus vector expressing HIV-1 genes was
associated with increased acquisition of HIV-1 infections in a subpopulation of vaccinees
(1–4). However, the recent modest success of a two-modality vaccine regimen (an HIV-1
Env protein and a recombinant canary pox construct expressing HIV-1 Env) in a population
of Thai volunteers (the RV144 trial) has renewed the focus of investigators on developing a
vaccine that can prevent infection with HIV-1 (5). The results of this trial showed vaccine
efficacy up to 3 years after initiating vaccination, with a 31.2% reduction in infection rate.
An effective or even a partially effective AIDS vaccine in humans or monkeys could prove
enormously instructive because it would provide an opportunity to explore immune and
genetic correlates of protection against virus acquisition. Elucidating the vaccine-elicited
immune responses that are associated with protection in vaccinees would create a rationale
for focusing attention on developing immunogens that generate such immune responses.
However, attempts to pursue such studies have been frustrated by the absence of even partial
protection against acquisition of HIV in humans or simian immunodeficiency virus (SIV) in
monkeys.
The present study was initiated to examine the protective efficacy of a plasmid DNA prime/
recombinant adenovirus serotype 5 (rAd5) boost vaccine regimen against acquisition of two
divergent SIV isolates by monkeys after low-dose repeat mucosal exposures to the virus.
Although this vaccine regimen differs from that used in the RV144 Thai trial, it has been
shown to induce robust immune responses to HIV-1 in humans and to SIV in monkeys.
Because the plasmid DNA prime/rAd5 boost vaccine regimen provided partial protection
against one of the SIV isolates in the study, we examined both immune and genetic
correlates of vaccine protection against SIV acquisition in this nonhuman primate model.
RESULTS
To evaluate vaccine protection in rhesus monkeys against repeated, mucosal challenge with
a pathogenic SIV isolate, we immunized Indian-origin rhesus monkeys with plasmid DNA
(4 mg per construct, intra-muscularly, at weeks 0, 4, and 8) and rAd5 vectors (1 × 1011
particles per construct, intramuscularly, at week 26) using vectors expressing SIVmac239
env and gag-pol. To assess vaccine protection against different SIV isolates, we challenged
monkeys about 4 months after the rAd5 boost with a quasi-species of either the closely
related SIV-mac251 or the genetically distant SIVsmE660.
The mucosal virus challenges were carried out weekly for 12 consecutive weeks by
intrarectal inoculations with one AID50 (median animal infectious dose) of virus challenge
stock. Plasma SIV RNA levels were assessed each week, and monkeys that had detectable
plasma virus were excluded from subsequent virus challenges. Three parallel studies were
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performed: (i) a two-arm experiment using Mamu-A*01–, Mamu-B*08–, and Mamu-B*17–
negative Indian-origin rhesus monkeys with an SIVmac251 challenge (n = 40) [these
monkeys did not express major histocompatibility complex (MHC) class I alleles that are
associated with the development of potent cytotoxic T lymphocyte responses that confer
protection against rapid SIV replication]; (ii) a two-arm experiment using Mamu-A*01–,
Mamu-B*08–, and Mamu-B*17–negative Indian-origin rhesus monkeys with an
SIVsmE660 challenge (n = 50); and (iii) a two-arm experiment using Mamu-A*01–positive
Indian-origin rhesus monkeys, with an SIVsmE660 challenge (n = 39). The control arm of
each of these experiments was composed of sham-vaccinated animals. The conditions used
in these virus challenge studies provided an 85% power to detect a 50% reduction in the per-
challenge risk of virus acquisition for the 50-monkey experiment and about a 75% power to
detect this effect size for the 40-and 39-monkey experiments (6).
The endpoints in each of these experiments were acquisition of infection and peak plasma
virus RNA concentrations. In the first experiment, vaccination had no impact on acquisition
of infection with SIVmac251, a virus that is very close in genetic sequence to the virus used
in the construction of the vaccine immunogens (Fig. 1A). Nevertheless, the experimentally
vaccinated group of monkeys had about a one-log10 lower peak plasma virus RNA level
than the group of sham-vaccinated monkeys (Fig. 1A).
In the second experiment, after 12 successive challenges, experimentally vaccinated
monkeys had about a 50% lower rate of infection with SIVsmE660 than the sham-
vaccinated monkeys (48% versus 88%, P = 0.001; Fig. 1B). This challenge virus is as distant
genetically from the sequence of the virus used in the construction of the vaccine
immunogens as two of the most genetically disparate clade-identical HIV-1 isolates (7).
Vaccination of these Mamu-A*01–negative rhesus monkeys had no effect on peak plasma
virus RNA concentrations after infection (Fig. 1B). In the third experiment in Mamu-A*01–
positive rhesus monkeys, experimentally vaccinated monkeys also had about a 50% lower
rate of infection with SIVsmE660 than the sham-vaccinated monkeys (Fig. 1C). In addition,
these experimentally vaccinated monkeys had about a one-log10 lower peak plasma virus
RNA concentration than the group of sham-vaccinated monkeys (37% versus 75%, P =
0.009; Fig. 1C). When the results of the second and third vaccine experiment were combined
for analysis, the statistical significance of the difference in SIVsmE660 acquisition between
experimentally vaccinated and sham-vaccinated monkeys was significant (Fig. 1D, P = 4 ×
10−5 with a log-rank test). Therefore, these experiments demonstrated protection against
acquisition of the SIVsmE660 isolate but not the SIVmac251 isolate. Moreover, they
showed that the effects of vaccination on virus acquisition and virus load after infection are
distinct, but that both effects can be manifest in the same group of vaccinated challenged
monkeys. No effect of the vaccine was apparent on set-point plasma virus RNA
concentration or loss of CD4+ T lymphocytes after SIV challenge in these cohorts of
monkeys (figs. S1 and S2).
The availability of these experimentally vaccinated monkeys in which about 50% were
protected from SIVsmE660 infection provided an opportunity to explore the immune
correlates associated with protection against acquisition of the virus. To examine possible
correlates without imposing a bias on the findings, we evaluated vaccine-elicited cellular
immune responses, innate responses, antibody responses, and host genetic factors. These
studies were done on both the Mamu-A*01–negative and the Mamu-A*01–positive animals
challenged with SIVsmE660. Given that these studies were done to define immune and
genetic determinants of vaccine protection, only the experimentally vaccinated monkeys
were evaluated. These vaccinated monkeys were divided into two groups: those that were
protected and those that became infected.
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SIV-specific cellular immune responses in the experimentally vaccinated monkeys were
evaluated by interferon-γ (IFN-γ) enzyme-linked immunospot (ELISpot) and intracellular
cytokine staining; total CD4+ and CD8+ T cell populations were characterized by
phenotypic profiling. Unfractionated peripheral blood mononuclear cells (PBMCs)
evaluated in a pooled peptide ELISpot assay for SIVmac239 Env-, Gag-, and Pol-specific
cellular immune responses on the day of challenge demonstrated no differences between the
infected and the uninfected monkeys (Fig. 2). PBMCs sampled at week 46, 16 weeks after
the rAd boost, were also evaluated by intracellular cytokine staining after pooled peptide
stimulation for SIV Env- and Gag-specific T cell responses. These studies were performed
with both SIVmac239 and SIVsmE543 peptide pools. No statistically significant differences
were noted between the infected and the uninfected monkeys in the magnitude of either the
CD4+ or the CD8+ T cell responses (Fig. 3). An evaluation of the polyfunctionality of these
cellular responses also did not differentiate between the monkeys that became infected and
the monkeys that did not become infected (Fig. 3). Finally, a phenotypic characterization of
the total CD4+ for expression of cell surface molecules associated with memory did not
differentiate the monkeys that became infected from the monkeys that did not become
infected (fig. S3).
Mediators of innate immune responses were also evaluated in these monkeys 4 weeks after
the rAd boost. Natural killer (NK) cell activity, assessed by determining
CD3−CD20−CD8+NKG2A+ PBMC expression of molecules associated with NK cell
activation and function, was comparable in the monkeys that did and did not become
infected (fig. S4). Further, Luminex technology was used to assess plasma concentrations of
a diversity of cytokines 4 weeks after the rAd boost. No differences were documented in the
patterns of cytokine expression in the vaccinated monkeys that became infected and in the
vaccinated monkeys that did not become infected (fig. S5). The anti-Env antibodies
generated by these vaccinated monkeys were assessed with binding, antibody-dependent
cellular cytotoxicity (ADCC), and neutralization assays. To evaluate serum binding to the
challenge virus, we determined ED50 (median effective dose) values for serum binding to
SIVsmE660 gp140 using serum sampled from both Mamu-A*01–positive and Mamu-
A*01–negative monkeys that were challenged with SIVsmE660 at both week 34 and day of
challenge time points. No statistically significant differences in these values were observed
between the vaccinated monkeys that became infected and those that did not become
infected (Fig. 4). The avidity of the anti-Env antibodies in these two groups of monkeys,
measured by sodium thiocyanate (NaSCN) sensitivity of antibody binding to Env protein,
did not differ (Fig. 4). Further, ADCC activity, as measured with recombinant Env protein–
pulsed target cells, was not different in these two groups of animals (Fig. 5).
Before initiating studies of vaccine-induced neutralizing antibody responses in these
vaccinated monkeys, we assessed the neutralization sensitivity of the challenge viruses.
Although the neutralization resistance of the SIVmac251 challenge stock has been well
documented, the neutralization phenotype of the SIVsmE660 stock had not been well
characterized. To evaluate the neutralization sensitivity of this SIVsmE660 virus stock, we
assayed pseudovirions generated from Env proteins of selected members of the virus quasi-
species in TZM-bl cells, and we also assayed the challenge stock itself in TZM-bl and
rhesus monkey PBMCs. Although some of the SIVsmE660 Env-based pseudovirions were
easy to neutralize (fig. S6A), the CR54-PK-2A5 pseudovirion displayed a more difficult to
neutralize (tier 2–like) phenotype (fig. S6B). The challenge stock virus quasi-species was
easy to neutralize in TZM-bl cells (fig. S7A), but was tier 2–like in rhesus monkey PBMCs
(fig. S7B). Therefore, this SIVsmE660 challenge virus exhibited intermediate sensitivity to
neutralization compared to the resistance to neutralization of most SIVmac239/251 stocks.
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To evaluate serum neutralization in pseudovirion-based assays, we generated pseudovirions
using two different transmitted/founder env genes selected from a separate cohort of
monkeys that were infected intrarectally; one pseudovirion had a tier 1– and the other a tier
2–like phenotype (Fig. 6). Assays were performed to assess neutralization by serum sampled
from these monkeys at peak immunity and day of challenge time points. Comparable
neutralization of the tier 1–like pseudovirion was demonstrated by serum from the
vaccinated monkeys that became infected and those that did not become infected (Fig. 6).
The sera sampled on the day of challenge from these two groups of monkeys also mediated
comparable neutralization of the tier 2–like pseudovirion when assessed by determining
ID50 (50% inhibitory dilution) values. However, a significantly lower titer-neutralizing
antibody response was measured in the day-of-challenge serum of the Mamu-A*01–
negative monkeys that became infected when assessed with the tier 2–like pseudovirion and
expressed as percent neutralization with a 1:10 serum dilution (P = 0.03) (Fig. 6).
A 1:50 dilution of plasma sampled from these monkeys at the time of the peak vaccine-
elicited immuneresponse was assessed in a neutralization assay with human PBMCs as
target cells and the challenge stock of SIVsmE660 as the replicating virus. A statistically
significant decrease in virus replication was observed with plasma from Mamu-A*01–
negative vaccinated monkeys that became infected compared with plasma from Mamu-
A*01–negative vaccinated monkeys that did not become infected (P = 0.008)(Fig.
7).Although a similar analysis of the plasmas sampled on the day of challenge did not show
a statistically significant difference in neutralization between these groups of monkeys in
this PBMC-based assay, the relative levels of neutralizing antibodies in the plasma of each
monkey in this assay were moderately correlated with those from week 38 (estimated
Spearman correlation = 0.40; P = 0.05). No correlate of protection against acquisition of
SIVsmE660 was observed when the vaccine-elicited immune responses in the Mamu-A*01–
positive rhesus monkeys were assessed in either the pseudovirion- or the PBMC target cell–
based neutralization assay.
We also evaluated genetic determinants that might have contributed to the protection from
infection observed in the monkeys. We have recently shown that the expression of particular
TRIM5 alleles (encoding the host restriction factor TRIM5) by rhesus monkeys is associated
with control of SIVmac251 replication both in vitro and in vivo (8, 9). Two alleles are
codominantly expressed at the TRIM5 locus of the rhesus monkey. If one or both of those
alleles are from the group of alleles 6 to 11 (permissive), SIV replication occurs at a higher
level than if both are from the group of alleles 1 to 5 (restrictive). To evaluate the
contribution of the expression of particular TRIM5 alleles to protection against infection, we
retrospectively determined the TRIM5 genotypes for all of the monkeys in these studies
(tables S2 and S3). We separated the common variants of TRIM5 into two groups: (i)
restrictive (1-5/1-5 or 1-5/TRIMCypA) and (ii) permissive (1-5/6-11, 6-11/6-11, or 6-11/
TRIMCypA). We excluded monkeys that had two TRIMcypA alleles (TRIMCypA/
TRIMCypA) from this analysis because TRIM5 alleles were deleted in these monkeys (3 of
89 monkeys).
When the sham-immunized monkeys were evaluated together as a single group regardless of
their Mamu-A*01 status, monkeys with at least one permissive TRIM5 allele were more
likely to acquire SIVsmE660 infection than those monkeys expressing restrictive alleles
(Fig. 8A) (P = 0.0023). Similarly, when vaccinated monkeys (Mamu-A*01− and Mamu-
A*01+) that were challenged with SIVsmE660 were assessed as one cohort, we observed a
statistically significant association between the expression of two restrictive alleles and
protection against virus acquisition (Fig. 8B) (P = 0.0013). Therefore, the expression of
TRIM5 alleles 1 to 5 was associated with protection from infection after low-dose
SIVsmE660 intrarectal exposures in rhesus monkeys regardless of vaccination status.
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Because this was a retrospective analysis, there were not enough monkeys that were
homozygous for TRIM5 alleles 6 to 11 to differentiate between the effect of having one
versus two permissive alleles on mucosal acquisition of infection. A protective effect of the
vaccine was observed in vaccinated monkeys regardless of their TRIM5 genotypes (Fig. 9).
Finally, using a logistic regression analysis, we assessed the relative contributions of
vaccine-elicited immune responses and genetic determinants of protection from infection in
vaccinated monkeys (details of analysis in the Supplemental Material). SIVsmE660
infection in vaccinated monkeys was the outcome variable used in the logistic regression
models. In the Mamu-A*01–positive animal study, the permissive TRIM5 phenotype was
the most significant covariate (Table 1; P = 0.008, estimated odds ratio (OR) of infection =
18). Once the permissive TRIM5 phenotype was in the model, no other covariate added
significantly to the model. In the Mamu-A*01–negative animal study, the first covariate
added was lack of SIVsmE660 neutralization as measured in PBMCs at week 38, the time of
peak vaccine-induced immune responses (P = 0.028, OR = 18.6). The second covariate
added was low SIVsmE660 Env-specific CD4+ T cell responses (P = 0.032, OR = 9.8). No
other covariates were subsequently significant. Therefore, low levels of virus neutralization
and low Env-specific CD4+ T cell responses were strong predictors of infection in the
Mamu-A*01–negative animals. When both the Mamu-A*01–positive and the Mamu-A*01–
negative monkeys were grouped together for analysis, the first covariate added to the model
(P = 0.005, OR = 31.7) was lack of restrictive TRIM5 alleles. Other statistically significant
covariates included Env-specific CD4+ T cell responses and neutralizing antibody responses
as measured with the pseudovirion/TZM-bl cell assay (Table 1).
DISCUSSION
Here, vaccination was associated with protection against infection with SIVsmE660 but not
SIVmac251. The sequences of SIVmac239, the virus used for generating the vaccine
immunogens, and the SIVmac251 isolate used for challenging the monkeys are very similar
(10). In contrast, the SIVsmE660 virus sequence is quite divergent from that of SIVmac239
(7). The sequence distance between SIVmac239 and SIVsmE660 is comparable to that of
two sequence-divergent isolates of clade B viruses. One might have expected better
protection against SIVmac251 challenge because vaccine-induced immune responses to
SIVmac239 should have been more cross-reactive with SIVmac251 than SIVsmE660. The
protection from mucosal acquisition of SIVsmE660 but not SIVmac251 in this vaccine
study may have been a consequence of differences in susceptibility to immune pressure,
tropism, or the replication capacity of these two viruses.
Although SIVmac239 and SIVmac251 are relatively resistant to antibody-mediated
neutralization, the neutralization profile of SIVsmE660 has not been well studied (11). We
demonstrated that pseudovirions generated with env genes isolated from a number of rhesus
monkeys infected with this virus quasi-species can be either highly sensitive (tier 1–like) or
relatively resistant (tier 2–like) to neutralization in a pseudovirion/TZM-bl neutralization
assay. We have also shown that the challenge stock of SIVsmE660 used in the present study
has tier 2–like properties when assessed for neutralization using PBMC target cells.
Although mucosal exposure of rhesus monkeys to SIV isolates is a powerful animal model
for studying sexual transmission of HIV-1 in humans, this model does have limitations. For
example, HIV-1 transmission is often facilitated in humans by cofactors such as local
mucosal lesions and coinfections. Because the transmission model used in the current study
does not include the induction of mucosal lesions in the experimental monkeys, it may prove
easier to block mucosal infections in this animal model than in humans.
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Although the recently completed RV144 Thai trial demonstrated vaccine-associated
protection in 31.2% of vaccinees at 3 years after the initiation of vaccination, no diminution
of virus load was seen in vaccinees who became infected (5). This observation has led to the
suggestion that it may be possible to elicit an immune response that can abort an HIV-1/SIV
infection at the portal of virus entry without an effect on subsequent virus replication if an
infection is initiated in a vaccinee. Here, in vaccinated monkeys that became infected after
repeated, low-dose intrarectal exposures to virus, the monkeys challenged with SIVmac251
had a lower peak plasma virus RNA level compared with control monkeys. This same effect
was seen in the Mamu-A*01–positive but not the Mamu-A*01–negative vaccinated
monkeys challenged with SIVsmE660. These data suggest that the relationship between
vaccine protection against acquisition of infection and virus replication after infection are
independent, one possibly mediated by the humoral immune response and the other by
cellular immunity.
We observed an association between a vaccine-induced neutralizing antibody response and
protection against SIVsmE660 acquisition, but this was found in Mamu-A*01–negative but
not Mamu-A*01–positive monkeys. The more robust antibody association was the
neutralizing antibody response measured in a PBMC neutralization assay, evaluated at the
time of peak antibody response after vaccination. An association between vaccine-induced
neutralizing antibodies and protection against virus acquisition was also observed with Env
pseudo-viruses that had a tier 2–like neutralization profile but not pseudoviruses with a tier
1–like profile. Moreover, an association was seen between protection and vaccine-induced
Env-specific CD4+ T cell responses. This cellular immune response might have provided
help in the generation of an anti-Env antibody response. Thus, three complementary findings
suggest that neutralizing antibodies may indeed be contributing to vaccine protection in this
model.
Although we have demonstrated in the present study that neutralizing antibodies may be
contributing to the protection of vaccinated monkeys, this finding does not rule out the
possibility that other vaccine modalities may provide protection against an AIDS virus
infection through different immune mechanisms. For example, it has been reported that
rhesus monkeys can be protected against SIVmac239 infection by vaccination with a
recombinant cytomegalovirus (CMV) vaccine vector (12). Because this vector induces
memory CD8+ T cell responses in mucosal tissues, it is possible that the protection induced
by recombinant CMV immunization is mediated by this cellular mechanism. It is also
possible that other vaccine modalities may confer more robust protection than the DNA/
rAd5 vaccine used here.
We have previously shown that the TRIM5 alleles expressed by individual monkeys have a
significant effect on the control of SIV replication in those animals, both in their
lymphocytes in vitro and in vivo after experimental infection (8, 9). Here, we show a strong
trend toward an effect of the expression of restricting TRIM5 alleles on mucosal acquisition
of SIVsmE660 infection even in the absence of vaccination. The complementary
contributions of TRIM5 haplotype and vaccine-induced immune responses for protection
have potentially important mechanistic implications. The antibody induced by vaccination
did not by itself confer sterile protection against infection. Given that a large multiplicity of
infection (MOI) of HIV-1 or SIV can override TRIM5α restriction, these findings suggest
that antibody binding to the SIV virions decreased the effective inoculum of infectious virus,
making the residual infectious virions susceptible to the TRIM5α-mediated restriction.
The vaccination approach used in this study, a plasmid DNA prime/rAd5 boost, was
developed to induce both CD8+ T lymphocyte responses and Env-specific antibody
responses. The exploration of immune correlates in the present study suggests that a
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neutralizing antibody may be the response that conferred protection against mucosal
acquisition of SIVsmE660. Our ability to also detect the genetic contribution to vaccine
protection may have been a consequence of the marginal protection afforded by these
vaccine modalities. It is possible that this vaccine may have protected monkeys from a
smaller inoculum of SIVmac251. It is also possible that a vaccine that elicits a potent




Monkeys used in this study were housed in accordance with the guidelines of the
Institutional Animal Care and Use Committee for Harvard Medical School and the Guide for
the Care and Use of Laboratory Animals [Institute of Laboratory Animal Resources (U.S.)
Committee on Care and Use of Laboratory Animals, 1996]. This study was approved by the
Harvard Medical Area Standing Committee on Animals (protocol number 03724; assurance
number A3431-01). Procedures were conducted under ketamine anesthesia, and all efforts
were made to minimize suffering.
Plasma SIV RNA concentrations
Plasma SIV RNA concentrations were determined with a modified two-step quantitative
reverse transcription–polymerase chain reaction (qRT-PCR) process based on that described
previously (13, 14). Experimental samples were run in parallel with an SIV-gag RNA
standard on an Applied Biosystems StepOne Real Time PCR System.
PBMC ELISpot assay
Multiscreen 96-well plates were coated overnight with 100 μl per well of anti-human IFN-γ
(5 μg/ml) (B27; BD Pharmingen) in endotoxin-free Dulbecco’s phosphate-buffered saline
(D-PBS). The plates were then washed three times with D-PBS containing 0.1% Tween 20,
blocked for 2 hours with D-PBS containing 5% fetal bovine serum (FBS) to remove the
Tween 20, and incubated with peptide pools and 2 × 105 PBMCs in triplicate in 100-μl
reaction volumes. The peptide pools spanning the entire SIVmac239 Env, Gag, or Pol
proteins comprised 15–amino acid peptides overlapping by 11 amino acids. Each peptide in
a pool was present at a 1 μg/ml concentration. After an 18-hour incubation at 37°C, the
plates were washed nine times with D-PBS containing 0.1% Tween 20 and once with
distilled water. The plates were then incubated with biotinylated rabbit anti-human IFN-γ (2
μg/ml) (Biosource) for 2 hours at room temperature, washed five times with D-PBS
containing 0.1% Tween 20, and incubated for 2.5 hours with a 1:500 dilution of
streptavidin–alkaline phosphatase (Southern Biotechnology). After three washes with D-
PBS containing 0.1% Tween 20 and three washes with D-PBS alone, the plates were
developed with bromochloroindolyl phosphate–nitro blue tetra-zolium (BCIP-NBT)
chromogen (Pierce), stopped by washing with tap water, air-dried, and read with an
ELISPOT reader (Cellular Technology Ltd.).
PBMC stimulation and intracellular cytokine staining
PBMCs were isolated from EDTA-anticoagulated blood and frozen in the vapor phase of
liquid nitrogen. Cells were later thawed and allowed to rest for 6 hours at 37°C in a 5% CO2
environment. The viability of these cells was >90%. PBMCs were then incubated at 37°C in
a 5% CO2 environment for 6 hours in the presence of RPMI/10% fetal calf serum alone
(unstimulated), a pool of 15-nucleotide oligomer Gag or Env peptides (2 μg/ml of each
peptide), or staphylococcal enterotoxin B (SEB) (5 μg/ml, Sigma-Aldrich) as a positive
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control. All cultures contained monensin (GolgiStop; BD Biosciences) as well as anti-CD28
(1 μg/ml) and anti-CD49d (1 μg/ml) (BD Biosciences). The cultured cells were stained with
monoclonal antibodies (mAbs) specific for cell surface molecules including CD3, CD4, and
CD8. After fixing with Cytofix/Cytoperm solution (BD Biosciences), cells were
permeabilized and stained with antibodies specific for IFN-γ, tumor necrosis factor–α
(TNF-α), and interleukin-2 (IL-2). Labeled cells were fixed in 1% formaldehyde–PBS.
Antibodies
The antibodies used in this study were directly coupled to fluorescein isothiocyanate (FITC),
phycoerythrin (PE), PE–Texas red (ECD), peridinium chlorophyll protein (PerCP)–Cy5.5,
PE-Cy7, AmCyan, Pacific Blue, allophycocyanin (APC), Alexa Fluor 700, and APC-Cy7.
All reagents were validated and titrated with rhesus monkey PBMCs. The following mAbs
were used: anti–TNF-α (MAb11), anti–IFN-γ (B27), anti–IL-2 (MQ1-17H12), anti-CD28
(L293), anti-CD95 (DX2), anti-CD3 (SP34-2), anti-CD8α (RPA-T8), anti-CD4 (L200),
anti-CD107a (H4A3), anti–MIP-1β (macrophage inflammatory protein–1β) (D21-1351),
anti-Ki67 (B56), anti-CCR5 (3A9), and anti-β7 (FIB504) (all from BD Biosciences). A
violet fluorescent reactive dye (ViViD; Invitrogen) was also used as a viability marker to
exclude dead cells in the analysis.
Intracellular cytokine staining assay for ADCC activity
An intracellular cytokine staining assay was used to measure SIV antibody–mediated NK
cell cytokine expression and degranulation. Target cells were prepared by incubation with
monomeric gp120 derived from SIVmac251 for 1 hour at room temperature, followed by
washing twice with ice-cold R10. Purified human NK cells were used as effector cells.
Target cells (250,000) were dispensed into each well of a 96-well plate. Diluted plasma (100
μl) was added to each well, and the target and antibody mixture was incubated for 15 min at
room temperature. Effector cells (250,000) were added to each well at an effector/target
ratio of 1:1. Cells were incubated for 4 hours in the presence of monensin and anti-CD107a.
At the end of the incubation, cells were washed and stained with antibodies specific for
CD3, CD20, CD56, and CD16 and the intracellular molecules IFN-γ, TNF-α, and MIP-1β.
Cells were washed and fixed in 1% paraformaldehyde. Human CD3−CD20−CD56+ NK cells
were evaluated for the expression of CD107a, IFN-γ, TNF-α, and MIP-1β.
Protein expression and enzyme-linked immunosorbent assay
SIVsmE660 gp140 protein was expressed with the expression plasmid SIVsmE660CR54-
PK.2A5 via transient transfection of FreeStyle 293-F cells (Invitrogen). The His-tagged
protein was purified over a diethyl-aminoethyl (DEAE) Sepharose resin followed by
immobilized metal affinity chromatography (IMAC) with a nickel chelation resin (Sigma).
Reacti-Bind ELISA (enzyme-linked immunosorbent assay) plates (Pierce) were coated with
200 ng of protein, and the plates were blocked with 200 μl per well of 150 mM NaCl, 50
mM tris-HCl, 1 mM EDTA, 3.3% FBS, 2% bovine albumin, and 0.07% Tween 20 (B3T
buffer) for 1 hour. Serial dilutions of plasma samples were diluted in B3T buffer and
incubated on assay plates for 1 hour. Biotin-conjugated goat anti-monkey IgG
(immunoglobulin G) antibody (Rockland Immunochemicals) was used as the secondary
antibody, followed by peroxidase-labeled streptavidin (Kirkegaard and Perry Laboratories).
The color reaction was carried out with 3,3′,5,5′-tetramethylbenzidine (Kirkegaard and
Perry Laboratories) for 30 min at ambient temperature, and the reaction was stopped with 1
N H2SO4. All other ELISA incubations were at performed 37°C. The reciprocal serum
dilution that demonstrated half-maximal binding (ED50) was calculated with a four-
parameter nonlinear regression equation with GraphPad Prism. Avidity ELISAs were
performed in a similar manner but included the chaotropic agent NaSCN. After addition of
plasma samples, plates were incubated with 1.5 M NaSCN for 15 min. Control plates were
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incubated with PBS. Avidity indices were calculated by dividing ED50 values with NaSCN
treatment by ED50 values without treatment.
Cytokine secretion
Twenty-three cytokines were measured in plasma with the nonhuman primate cytokine
Milliplex kit (Millipore) according to the manufacturer’s instructions. The cytokines
included IL-1α, IL-1RA (IL-1 receptor antagonist), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10,
IL-12/23 (p40), IL-13, IL-15, IL-17, IL-18, IFN-γ, G-CSF (granulocyte colony-stimulating
factor), GM-CSF (granulocyte-macrophage colony-stimulating factor), MCP-1 (monocyte
chemotactic protein-1), MIP-1α (macrophage inflammatory protein 1α), MIP-1β, TNF-α,
TGF-β (transforming growth factor–β), sCD40L (soluble CD40 ligand), and VEGF
(vascular endothelial growth factor). Plasma was incubated with antibody-coupled beads
overnight followed by incubation with biotinylated detection antibody and, finally,
incubation with streptavidin-PE. Each sample was assayed in duplicate, and cytokine
standards supplied by the manufacturer were run on each plate. Multianalyte profiling was
performed with a Luminex-100 system, and data were analyzed with BioPlex manager
software (Bio-Rad). One additional analyte was measured with a human IFN-α ELISA kit
(PBL Interferon Source).
Pseudovirion-based neutralization assay
Neutralizing antibody responses against SIVsmE660 Env pseudo-viruses were measured
with a luciferase-based assay in TZM-bl cells [obtained through the National Institutes of
Health (NIH) AIDS Research and Reference Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases (NIAID), NIH from J. C. Kappes, X. Wu, and
Tranzyme Inc.] as previously described (15, 16). Briefly, threefold serial dilutions of pre-
and post-immune sera were performed in duplicate (96-well flat bottom plate) in 10%
DMEM (Dulbecco’s modified Eagle’s medium) growth medium (100 μl per well). Two
hundred TCID50 (median tissue culture infectious dose) of virus was added to each well in a
volume of 50 μl, and the plates were incubated for 1 hour at 37°C. TZM-bl cells were then
added (1 × 104 per well in 100-μl volume) in 10% DMEM growth medium containing
DEAE-dextran (Sigma) at a final concentration of 11 μg/ml. Assay controls included
replicate wells of TZM-bl cells alone (cell control) and TZM-bl cells with virus (virus
control). After a 48-hour incubation at 37°C, 150 μl of assay medium was removed from
each well and 100 μl of Bright-Glo luciferase reagent (Promega) was added and
luminescence was measured. The ID50 titer was calculated as the serum dilution that caused
a 50% reduction in relative luminescence units (RLUs) compared to the virus control wells
after subtraction of cell control RLUs. Assay stocks of molecularly cloned SIVsmE660
CP3C-P-A8 (tier 1) and CR54-PK-2A5 (tier 2) Env-pseudotyped viruses were prepared by
cotransfecting 293T/17 cells with an Env-expressing plasmid and an Env-deficient backbone
plasmid (SIVmac239deltaEnv), as previously described (15, 17).
PBMC-based neutralization assays
Whole blood (50 ml) was obtained from healthy human donors (Research Blood
Components), and PBMCs were purified by Ficoll-Hypaque centrifugation. PBMCs were
incubated in concanavalin A (6.25 μg/ml) and IL-2 (20 U/ml) for 2 days and then depleted
of CD8+ T cells with the EasySep Human CD8 Positive Selection Kit (Stem Cell
Technologies). CD8+ T cell–depleted PBMCs were subsequently infected with 0.01 MOI of
SIVsmE660 and incubated for 2 days. Plasma from vaccinated uninfected animals was heat-
inactivated for 60 min at 50°C. SIVsmE660-infected PBMCs (1 × 105) were incubated with
1:50, 1:250, or 1:1250 dilutions of heat-inactivated plasma for 5 days. Culture supernatants
(5 μl) were harvested and applied to 2 × 104 TZM-bl cells and incubated for an additional 2
days. TZM-bl cells were analyzed for luciferase activity with the Steady-Glo Luciferase
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Assay System (Promega). Relative viral replication was reported as the luciferase activity
generated by culture supernatants of infected PBMCs incubated with plasma from
vaccinated animals divided by the activity generated by infected PBMCs cultured with
plasma from a control unvaccinated animal. Neutralization assays in rhesus PBMCs were
performed as described (18), with the exception that PBMCs were stimulated overnight with
a higher concentration of PHA-P (phytohemagglutinin P) (10 μg/ml). Neutralization
potency was determined by reductions in p27 Gag antigen synthesis (Advanced BioScience
Laboratories Inc., catalog no. 5450).
TRIM5 genotyping
Genomic DNA was isolated from lymphocytes from rhesus monkeys with QIAamp DNA kit
(Qiagen) and sequenced for TRIM5 exons.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Protection against SIV acquisition and peak plasma virus RNA concentrations after
infection. Low-dose virus challenges involved weekly intrarectal inoculations with one
AID50 of virus challenge stock for 12 consecutive weeks. Plasma SIV RNA concentrations
were assessed weekly, and monkeys that had detectable plasma virus were excluded from
subsequent virus challenges. Shown are Kaplan-Meier curves for SIV acquisition and peak
plasma SIV RNA concentrations during primary infection. (A to C) Three parallel studies
were performed: (A) a two-arm experiment with Mamu-A*01–negative rhesus monkeys and
an SIVmac251 challenge (n = 40); (B) a two-arm experiment with Mamu-A*01–negative
rhesus monkeys and an SIVsmE660 challenge (n = 50); and (C) a two-arm experiment with
Mamu-A*01–positive rhesus monkeys and an SIVsmE660 challenge (n = 39). The control
arm of each of these experiments comprised sham-vaccinated animals. (D) The results of the
two SIVsmE660 challenge studies were combined and displayed as a single study. The
differences between the two groups of monkeys in acquisition of infection and in peak
plasma virus RNA concentrations were analyzed by the log-rank test and by the Wilcoxon
rank-sum test, respectively.
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Vaccine-induced pooled peptide ELISpot responses to SIV proteins. Monkey PBMCs were
assessed in a pooled peptide ELISpot assay for SIVmac239 Env-, Gag-, and Pol-specific
cellular immune responses on the day of challenge. Each plotted data point represents the
sum of spot-forming cell (SFC) responses for PBMCs of an individual monkey specific for
SIVmac239 Env, Gag, and Pol. Data points are for two studies: the Mamu-A*01–negative
monkeys challenged with SIVsmE660 and the Mamu-A*01–positive monkeys challenged
with SIVsmE660. In each study, the monkeys were divided into two groups: vaccinated
monkeys that became infected and vaccinated monkeys that did not become infected. No
statistically significant differences between the magnitudes of the responses in these groups
in each study were noted as determined by the Mann-Whitney test.
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Vaccine-induced virus-specific cellular immune responses. (A and B) PBMCs isolated from
Mamu-A*01–negative (A) and Mamu-A*01–positive (B) monkeys after the boost
immunization were exposed to pools of overlapping peptides spanning the Gag or Env
proteins of SIVsmE660, and the fractions of CD4+ or CD8+ T cells producing IFN-γ (F),
TNF-α (T), or IL-2 (2) were determined by intracellular cytokine staining. Data are
presented as the frequency of cytokine-producing CD4+ or CD8+ T cells from the groups of
monkeys. The cytokine profiles of these cells were determined by expressing each cytokine
response as a proportion of the total antigen-specific cytokine-producing CD4+ and CD8+ T
cell response. Data were analyzed with the SPICE software and are presented in pie charts
as the mean values from the experimental groups of monkeys. No statistically significant
differences between the magnitudes of the responses in these groups in each study were
noted as determined by the Mann-Whitney test.
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Vaccine-induced antibody binding to SIVsmE660. (A) Sera sampled 2 weeks after the rAd5
boost (week 34) and from the day of first SIVsmE660 viral challenge (week 53) were
assayed by ELISA for the level of antibody binding to SIVsmE660 gp140. Values are the
reciprocal plasma dilution yielding 50% half-maximal binding (ED50). (B) Avidity index
values from sera on the day of challenge. Avidity indices were calculated by dividing ED50
values with NaSCN treatment by ED50 values without treatment. P values were calculated
with a Mann-Whitney rank-sum test.
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Vaccine-induced antibody-dependent cell-mediated cytotoxicity responses to
SIVmac251gp120. CD3−CD20−CD56+ human PBMCs (NK cells) were incubated with
SIVmac251gp120-coated CEM-NKr-CCR5 target cells and plasma sampled from the
monkeys on the day of challenge. The expression of CD107a, IFNγ, TNF-α, and MIP-1β by
the NK cells was evaluated by intracellular cytokine staining. Data are expressed as
percentage of NK cells expressing these molecules. No statistically significant differences
between the magnitudes of the responses in these groups in each study were noted as
determined by the Mann-Whitney test.
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Neutralization of tiers 1 and 2 SIVsmE660 Env pseudoviruses. (A to D) Serum samples
were obtained from Mamu-A*01–negative (A and B) or Mamu-A*01–positive (C and D)
monkeys 2 weeks after rAd boost immunization or on the day of challenge (DOC) and were
tested for neutralizing activity against tier 1 (CP3C-P-A8) or tier 2 (CR54-P-2A5)
SIVsmE660 Env pseudoviruses with the TZM-bl assay. Data are presented as serum ID50
titer (A and C) or percent neutralization (B and D) at a 1:10 serum dilution. Immunized
monkeys are grouped retrospectively according to their infection status after SIVsmE660
challenge. Serum-neutralizing antibody activity from sham-vaccinated monkeys (control) is
shown in (B) and (D). Data points represent responses from individual monkeys, with the
median response indicated by the bar. P values were calculated with a Mann-Whitney rank-
sum test.
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Neutralization of SIVsmE660 in human PBMCs. CD8+ T cell–depleted, concanavalin A–
stimulated human PBMCs were infected at a low MOI with SIVsmE660. Infected PBMCs
were subsequently cultured in the presence of a 1:50 dilution of plasma collected from the
Mamu-A*01–negative and Mamu-A*01–positive study animals at 6 weeks after rAd
vaccination (peak). Virus from the infected PBMC-plasma coculture supernatant was
quantified with the TZM-bl assay. Luciferase assay results were normalized to a control
plasma and plotted as a relative viral replication. P values were calculated with a Mann-
Whitney rank-sum test.
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Effect of TRIM5 genotype on SIV mucosal infection in naïve and vaccinated monkeys. The
effect of restrictive or permissive TRIM5 alleles on the percentage of monkeys that
remained un-infected after each weekly intrarectal SIVsmE660 exposure is shown in
Kaplan-Meier curves. (A and B) Naïve (A) and vaccinated (B) monkeys were divided into
two groups: one group expressing only restrictive TRIM5 alleles (black) and the other
expressing at least one permissive allele (red). In the control group, 16 monkeys expressed
restrictive TRIM5 alleles, whereas 27 monkeys expressed permissive alleles. In the vaccine
group, 15 monkeys expressed restrictive alleles, whereas 28 monkeys expressed permissive
alleles. The statistical comparisons between monkeys with restrictive and permissive TRIM5
genotypes in control and vaccinated arms were determined by the log-rank test.
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Effect of vaccination on SIV mucosal infection. The effect of vaccination on the percentage
of monkeys with either restrictive or permissive TRIM5 genotypes that remain uninfected
after each weekly intrarectal SIVsmE660 exposure is shown in Kaplan-Meier curves. (A and
B) TRIM5 restrictive (A) or permissive (B) monkeys were divided into control (black) and
vaccinated (red) groups. The statistical comparisons between monkeys in control and
vaccinated arms for TRIM5 restrictive and permissive genotypes were determined by the
log-rank test.
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